Rejoyn at 24 months — what the first FDA-authorised prescription DTx for depression actually did to the market
- Rejoyn (Otsuka / Click Therapeutics) received FDA De Novo authorisation in April 2024 as the first prescription digital therapeutic for adjunctive treatment of MDD symptoms in adults on antidepressants. By April 2026 it has been on the US market for roughly 18 months.
- The authorisation trial (MIRAI, N=386) showed a between-group MADRS difference of roughly 2 points versus sham — statistically significant, clinically modest. Efficacy is in the "augmentation" range, not monotherapy.
- Core mechanism: six weeks of daily emotional-faces training (an implicit cognitive control task adapted from affective neuroscience) plus brief CBT lessons. 17-20 minutes per day.
- Real-world adoption signal: CMS 2026 DMHT codes, Highmark/BCBS coverage announcements in late 2025, and Otsuka's commercial relaunch with a $99/month cash-pay option for uninsured patients. Early post-launch discontinuation rates high (industry estimate ~45% at week 3).
The Rejoyn story is the first case study of what it actually takes to move a prescription digital therapeutic from FDA authorisation into clinical use. Two years in, the answer is: not much of a clinical revolution, and a useful regulatory template.
What changed in the market
Clinically, Rejoyn is augmentation. The 2-point MADRS advantage is comparable to low-dose atypical augmentation, without the metabolic side effects. For a subset of patients who tolerate a daily 20-minute app but not a second pill, that trade is rational. For most patients, it is another thing to remember.
Regulatorily, Rejoyn did the work. The De Novo path it established (DEN230063, regulation 21 CFR 882.5801) is the template every mental-health DTx since has followed. That regulatory plumbing is why the CMS 2026 DMHT code expansion (see the parallel piece in this issue) is possible.
Commercially, adoption has been slow. Physicians do not prescribe what insurance does not reliably cover. Insurance does not cover what physicians do not prescribe. The CMS 2026 codes break that loop on the billing side. Whether that translates into sustained uptake is the open question.
The 45% early discontinuation figure is the other half of the story. Digital therapeutics do not sustain engagement in the open market the way they do in trials. This is the same pattern seen in consumer mental-health apps — the drop-off curve is steep regardless of prescription status.
For your practice
US clinicians: if you have antidepressant-treated patients with residual symptoms who explicitly decline augmentation or who have already failed atypical augmentation, Rejoyn is a defensible referral. Set expectations honestly — modest augmentation effect, daily engagement required. Have a plan for week-3 drop-off: this is where most patients disengage.
Non-US clinicians: the authorisation does not translate, but the template does. In the next 2-4 years expect DTx approvals in your jurisdictions for MDD, ADHD, GAD, insomnia, and substance use disorders. The questions to ask then are the same ones raised by Rejoyn: how large is the adjunctive effect, what is the engagement curve, what is the dropout, and who is the patient for whom this is a genuine alternative.
For therapists generally: DTx do not compete with psychotherapy. They compete with pharmacological augmentation. Frame the conversation accordingly.
The question with digital therapeutics is not whether they work, but whether they move the market. Rejoyn's answer at 24 months: yes on regulatory plumbing, unfinished on clinical uptake.
Commercial data are industry estimates, not peer-reviewed. Long-term effectiveness beyond the 6-week trial window not yet established in real-world cohorts.